Download PDF
Rev Bras Ginecol Obstet 2016; 38(07): 365-367
DOI: 10.1055/s-0036-1586161
Case Report
Thieme Publicações Ltda Rio de Janeiro, Brazil

Mature Cystic Teratoma of Ovary with Abnormally High Levels of Ca19-9: A Case Report

Teratoma maduro cístico do ovário com níveis aberrantes de Ca19-9: caso clínico
Joana Sampaio
1   Department of Gynecology and Obstetrics, Hospital Pedro Hispano, Senhora da Hora, Porto, Portugal
,
Inês Sarmento-Gonçalves
1   Department of Gynecology and Obstetrics, Hospital Pedro Hispano, Senhora da Hora, Porto, Portugal
,
Joana Moreira Barros
1   Department of Gynecology and Obstetrics, Hospital Pedro Hispano, Senhora da Hora, Porto, Portugal
,
Joana Felix
1   Department of Gynecology and Obstetrics, Hospital Pedro Hispano, Senhora da Hora, Porto, Portugal
,
Pedro Tiago-Silva
1   Department of Gynecology and Obstetrics, Hospital Pedro Hispano, Senhora da Hora, Porto, Portugal
› Author Affiliations
Further Information

Publication History

02 March 2016

10 June 2016

Publication Date:
19 July 2016 (online)

   Permissions and Reprints

Abstract

Mature cystic teratomas, or dermoid tumors, are the most common benign ovarian neoplasms in young women. Malignant transformation is rare, and occurs in less than 2% of the cases. The heterogeneous histological composition of these tumors may be responsible for the occasional elevation of various tumor markers, such as Ca19–9 and Ca125. We describe one case of mature cystic teratoma in a 50-year old woman with the second highest level of Ca19–9 (8922.76 UI/mL) described in the literature. We concluded that abnormal levels of Ca19–9 are not necessarily associated with ovarian malignancy, and may lead to unnecessary medical intervention and patient anxiety. Therefore, the clinical features, imaging studies and antigen testing should be interpreted carefully, and should not limit the surgical approach.

Resumo

Os teratomas maduros císticos do ovário, ou tumores dermoides, são as neoplasias benignas mais frequentes em mulheres jovens. A sua transformação maligna é rara, e ocorre em menos de 2% dos casos. A composição histológica heterogénea destes tumores pode ser responsável pela ocasional elevação de marcadores tumorais, como o Ca19–9 e o Ca125. Descrevemos um caso de teratoma maduro cístico do ovário numa paciente de 50 anos com o segundo valor mais elevado de Ca19–9 (8922,76 UI/mL) descrito na literatura. Concluímos que níveis anormalmente elevados de Ca19–9 não estão necessariamente associados a tumores malignos, e podem conduzir a intervenções médicas desnecessárias e contribuir para o aumento da ansiedade da paciente. Portanto, as características clínicas, os estudos imagiológicos e os marcadores tumorais devem ser interpretados cuidadosamente, e não devem limitar o tipo de conduta cirúrgica.

Keywords

Ca19–9 - tumor markers - mature cystic teratoma - ovarian teratoma - dermoid cyst

Palavras-chave

Ca19–9 - marcadores tumorais - teratoma maduro cístico - teratoma ovárico - quisto dermoide
 

  • References

  • 1 Park CH, Jung MH, Ji YI. Risk factors for malignant transformation of mature cystic teratoma. Obstet Gynecol Sci 2015; 58 (6) 475-480
    CrossrefPubMedGoogle Scholar
  • 2 Atabekoğlu C, Bozaci EA, Tezcan S. Elevated carbohydrate antigen 19-9 in a dermoid cyst. Int J Gynaecol Obstet 2005; 91 (3) 262-263
    CrossrefPubMedGoogle Scholar
  • 3 Ulkumen BA, Goker A, Pala HG, Ordu S. Abnormal elevated Ca 19–9 in the dermoid cyst: a sign of the ovarian torsion?. Case Rep Obstet Gynecol 2013; 20 (13) 860-505
    PubMedGoogle Scholar
  • 4 Madaan M, Puri M, Sharma R, Kaur H, Trivedi SS. Unusually high levels of Ca19–9 associated with mature cystic teratoma of the ovary. Case Rep Obstet Gynecol 2014; 2014: 187910
    PubMedGoogle Scholar
  • 5 Cho HY, Kim K, Jeon YT, Kim YB, No JH. CA19-9 elevation in ovarian mature cystic teratoma: discrimination from ovarian cancer - CA19-9 level in teratoma. Med Sci Monit 2013; 19: 230-235
    CrossrefPubMedGoogle Scholar
  • 6 Dede M, Gungor S, Yenen MC, Alanbay I, Duru NK, Haşimi A. CA19-9 may have clinical significance in mature cystic teratomas of the ovary. Int J Gynecol Cancer 2006; 16 (1) 189-193
    CrossrefPubMedGoogle Scholar
  • 7 Ito K. CA19-9 in mature cystic teratoma. Tohoku J Exp Med 1994; 172 (2) 133-138
    CrossrefPubMedGoogle Scholar
  • 8 Kataoka T, Watanabe Y, Hoshiai H. Retrospective evaluation of tumor markers in ovarian mature cystic teratoma and ovarian endometrioma. J Obstet Gynaecol Res 2012; 38 (8) 1071-1076
    CrossrefPubMedGoogle Scholar
  • 9 Ustunyurt E, Gungor T, Iskender C, Ustunyurt BO, Bilge U, Mollamahmutoglu L. Tumor markers in mature cystic teratomas of the ovary. Arch Gynecol Obstet 2009; 279 (2) 145-147
    CrossrefPubMedGoogle Scholar
  • 10 Suh DS, Moon SH, Kim SC, Joo JK, Park WY, Kim KH. Significant simultaneous changes in serum CA19-9 and CA125 due to prolonged torsion of mature cystic teratoma of the ovary. World J Surg Oncol 2014; 12: 353
    CrossrefPubMedGoogle Scholar
  • 11 Pyeon SY, Park JY, Ki KD, Lee JM. Abnormally high level of CA-19-9 in a benign ovarian cyst. Obstet Gynecol Sci 2015; 58 (6) 530-532
    CrossrefPubMedGoogle Scholar
  • 12 Saba L, Guerriero S, Sulcis R, Virgilio B, Melis G, Mallarini G. Mature and immature ovarian teratomas: CT, US and MR imaging characteristics. Eur J Radiol 2009; 72 (3) 454-463
    CrossrefPubMedGoogle Scholar
  • 13 Parithivel K, Jagannathan JP, Krajewski K , et al. Ovarian squamous cell carcinoma arising from mature cystic teratoma. Cancer Imaging 2011; 11: 67-69
    PubMedGoogle Scholar
  • 14 Kudva R, Ayachit GS, Ayachit A. Malignant melanoma arising in an ovarian mature cystic teratoma - a rare entity. J Clin Diagn Res 2015; 9 (4) ED14-ED16
    CrossrefPubMedGoogle Scholar
  • 15 Frimer M, Seagle BLL, Chudnoff S, Goldberg GL, Shahabi S. Role of elevated cancer antigen 19-9 in women with mature cystic teratoma. Reprod Sci 2014; 21 (10) 1307-1311
    CrossrefPubMedGoogle Scholar